Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; ...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) ...
Cullinan Therapeutics (CGEM) will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager. These data and the study schema for a planned Phase 1b study in patients with moderate to ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory ...
BOSTON, March 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory ...
Fate Therapeutics, Inc. downgraded to Hold as FT819 SLE progress lags; Phase 1 shows promise but catalysts slip to 2H 2026.
There is increasing evidence on the involvement of Toll-like receptor 7 (TLR7) in the pathogenesis of systemic lupus erythematosus (SLE). At the recent American College of Rheumatology meeting, ...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) ...
CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results